Findings

What do systematic reviews say?

6 questions · 6 findings · 4 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 66.7%High 1 · 16.7%

Anti‐VEGF vs sham

Gain of 15 letters or more of visual acuity at 6 months · macular oedema secondary to branch retinal vein occlusion

Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity at 6 months compared with sham (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
RR 1.72 [1.19, 2.49]
1 study · 283 participants
Moderate

Anti‐VEGF vs steroids

BCVA: gain of 15 or more ETDRS letters · people with BRVO

Anti‐VEGF leads to higher gain of 15 letters or more of visual acuity compared with steroid (high certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
RR 1.67 [1.33, 2.1]
2 studies · 330 participants
High

Anti‐VEGF vs laser

BCVA: gain of 15 or more ETDRS letters · people with BRVO

Anti‐VEGF probably leads to higher gain of 15 letters or more of visual acuity compared with laser (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
RR 2.09 [1.44, 3.05]
2 studies · 201 participants
Moderate

Radiotherapy combined with anti‐VEGF vs anti‐VEGF alone

Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with neovascular AMD

Radiotherapy combined with anti‐VEGF probably leads to higher loss of 3 or more lines of best‐corrected visual acuity Measured… compared with anti‐VEGF alone (moderate certainty).

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
RR 2.11 [1.4, 3.17]
Studies not reported
Moderate

Anti‐VEGF vs control

BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher gain of 15 or more letters visual acuity at 1 year compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 4.19 [2.32, 7.55]
6 studies · 2667 participants
Moderate

Anti‐vascular endothelial growth factor (anti‐VEGF) with or without pan‐retinal photocoagulation (PRP) vs PRP alone

Progression to visual loss (loss of 3 or more lines on logMAR chart) · proliferative diabetic retinopathy

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found